Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech failure, 2002 -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (67)	5/20/2002 12:26:49 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 130

Agree with everything you said. I have looked at IMCL results and trial design for years, and my conclusion was that they were designed to burn time. Never imagined that weak management teams could burn us like this. Remember, virtually everyone was going "huh?" when Bristol Knows Squibb signed the deal. Feuerstein is generally on the mark with this story, but he was WRONG when he said "disappointing news for a wildly hyped drug that seems unable to live up to its billing". It was of interest before BMY signed the deal, but it was hardly one of biotech's focal points. Sorry that I forgot to point at CC. My point was that the monotherapy results are good. They are, first blush. I agree, the trial size again leaves us short of "decision time" data. But I don't think that OSIP and ABGX should dive to the ground tomorrow. Frustrating..... I've always looked at IMCL as a slow moving curiosity. And now we can't shake their stain on the sector.